Merck is testing a confluence of potential chart support near the $55 level. The stock of pharmaceutical company Merck (ticker, MRK) has been bloodied a…

Merck is testing a confluence of potential chart support near the $55 level. The stock of pharmaceutical company Merck (ticker, MRK) has been bloodied a…
This content is only available to subscribers. Sign up today!
This content is only available to subscribers. Sign up today!
Beleaguered pharmaceutical stocks have hit our targeted downside level that could inspire a bounce, at least. Just as there are leading stocks, sectors, etc. on…
A popular pharmaceutical ETF is testing its (ill-fated?) post-2009 bull market trendline. As the major stock averages continue to bide their time in sideways fashion,…
The post-2009 bull market in drug stocks is currently being threatened. In the midst of the selling pressure last week, we mentioned that several indices…
We have written many times about the challenge of weighing positive vs.negative inputs when analyzing the attractiveness of the investment climate. Often times, that applies…